# Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

> **NCT03061188** · PHASE1 · COMPLETED · sponsor: **Northwestern University** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Neoplasm
- Aggressive Non-Hodgkin Lymphoma
- Recurrent Solid Neoplasm
- Refractory Mantle Cell Lymphoma
- T-Cell Non-Hodgkin Lymphoma
- Unresectable Solid Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Pharmacological Study
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT03061188
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2018-03-11
- **Final completion:** 2020-08-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-06-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061188, "Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03061188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*